CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount. CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and ...

Accusing CSL of a “disgraceful” approach to bargaining, the CSL Behring workers are taking the protected action as the company puts out a revised offer to workers following the voting down of a ...

Forget one of one: this particular BMW 3.0 CSL is, quite literally, the very first M race car, and it’s up for sale for presumably many dollars. The very first official BMW M project was the 3.0 CSL.

Our fair value estimate is 30% higher than CSL's analyst price target of US$248 In this article we are going to estimate the intrinsic value of CSL Limited (ASX:CSL) by projecting its future cash ...

Some of Australia’s largest blue-chip investors have been caught on the wrong side of one of the year’s most crowded trades after piling into CSL as an alternative to holding a big position in ...

CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF), an Australian biotech focused on developing vaccines and blood-derived therapies, on Tuesday announced plans to invest approximately $1.5B in the U.S. over the ...

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...

Carlisle Companies (CSL) has been on investors’ radars this week, with recent price movements providing an opportunity for a closer look. The stock’s performance this month stands out when compared to ...

Health editor Michael Smith on CSL’s remarkable story, why investors have fallen out of love with the healthcare giant and what Trump has to do with it. CSL was run like a bureaucracy until 1990 when ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...